Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Year in Review
LBCL 2022 - Year in Review
LBCL 2022 - Year in Review
Year in Review
OUTREACH Primary Analysis and Patient-Reported Outcomes
LBCL 2022 - Year in Review
Dr Jeremy Abramson reviews data from the primary analysis of the OUTREACH study in addition to patient-reported outcomes, highlighting the potential for liso-cel utilization in the outpatient and community settings.
Read More ›
Year in Review
OUTREACH Study Found Outpatient Monitoring for Liso-cel to Be Feasible
LBCL 2022 - Year in Review
OUTREACH study evaluating liso-cel in patients with R/R LBCL after ≥2 lines of therapy deemed outpatient monitoring feasible with potential cost savings.
Read More ›
Year in Review
Patient-Reported Outcomes and Health-Related Quality of Life from the OUTREACH Study
LBCL 2022 - Year in Review
Results from the OUTREACH study demonstrate that HR-QoL was either improved or maintained from baseline in most patients with R/R LBCL who received liso-cel after ≥2 lines of therapy.
Read More ›
Year in Review
Phase 1 CARBON Study Demonstrated Clinical Benefits with Allogeneic CAR-T Therapy CTX110 in Patients with R/R LBCL
LBCL 2022 - Year in Review
Results from the phase 1 study of CTX110 highlighted the potential for immediate “off-the-shelf” availability of CAR-T therapy with demonstrated clinical benefits in R/R LBCL.
Read More ›
Year in Review
Long-Term Survival Following Relapse or Progression Post‒CAR-T in Patients with R/R LBCL Based on Real-World Data
LBCL 2022 - Year in Review
A real-world analysis of patients with R/R LBCL who experienced relapse or progression following CAR-T therapy found that approximately 20% achieved long-term survival.
Read More ›
Year in Review
Effectiveness of CAR-T Therapy in Double-Hit and Double-Expressor Lymphomas
LBCL 2022 - Year in Review
A multicenter, retrospective analysis evaluating survival outcomes with CAR-T reported median progression-free survival and median overall survival in double-hit and double-expressor lymphomas mirror data reported for patients with DLBCL.
Read More ›
Year in Review
ZUMA-7 Subsequent Therapies and Real-World Outcomes of Axi-cel for LBCL by Race and Ethnicity
LBCL 2022 - Year in Review
Dr Jeremy Abramson examines outcomes for patients in ZUMA-7 receiving subsequent treatment and real-world outcomes of axi-cel for LBCL by race and ethnicity, highlighting the need for better equity in access to CAR-T therapy.
Read More ›
Year in Review
Association of Metabolic Tumor Volume and Clinical Outcomes in the ZUMA-7 Study
LBCL 2022 - Year in Review
Analysis of MTV and clinical outcomes in patients with relapsed or refractory LBCL suggests that MTV is a more accurate and sensitive measure of tumor burden versus sum of product diameters.
Read More ›
Year in Review
Outcomes of Subsequent Therapies Following Axi-cel for Second-Line Treatment of Relapsed or Refractory LBCL in the ZUMA-7 Study
LBCL 2022 - Year in Review
Analysis of patients in ZUMA-7 who necessitated further therapy revealed that re-treatment with CAR-T therapy may be viable after an initial response in the 2L setting.
Read More ›
Year in Review
Real-World Outcomes of Axi-cel for LBCL by Race and Ethnicity
LBCL 2022 - Year in Review
Real-world analysis of outcomes with axi-cel in patients with LBCL by race and ethnicity revealed favorable response rates, with lower response rates observed in African-American patients.
Read More ›
Page 1 of 3
1
2
3
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Supported through funding by
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us